.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Federal Trade Commission
Cipla
McKinsey
Teva
Chubb
Cerilliant
Covington
Fuji
Harvard Business School

Generated: January 22, 2018

DrugPatentWatch Database Preview

US Patents With Foreign Priority to Switzerland Patent: 1797/97

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Citius PharmsSUPRENZAphentermine hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL202088-001Jun 13, 2011DISCNNoNo➤ Subscribe➤ SubscribeY
Citius PharmsSUPRENZAphentermine hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL202088-002Jun 13, 2011DISCNNoNo➤ Subscribe➤ SubscribeY
Citius PharmsSUPRENZAphentermine hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL202088-003Mar 27, 2012DISCNNoNo➤ Subscribe➤ SubscribeYWITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist